Skip to main content
. 2019 Jun 21;21(11):1423–1435. doi: 10.1093/neuonc/noz107

Fig. 6.

Fig. 6

SHP099 in combination with TMZ extends the survival of GBM-bearing animal. (A and E) Treatment scheme for the evaluation of in vivo efficacy of SHP099 in combination with TMZ in Ink4a/Arf−/− mAsts (A) or GSC 157 (E) tumor xenografts. The mice were treated with indicated 100 mg/kg SHP099 with or without 8 mg/kg TMZ from Monday to Friday within 2 weeks. (B and C) Representative images (B) on day 20 and quantitation of BLI at the indicated date (C) of Ink4a/Arf−/− mAst xenografts with ectopic expression of PDGFRα and PDGF-A from SHP099 treated and control mice. (D) Kaplan–Meier survival analysis of animals with Ink4a/Arf−/− mAst tumors (n = 10 per group). (F and G) Representative images on day 50 (F) and quantitation of BLI at the indicated date (G) of GSC 157 tumor xenografts from SHP099 treated and control mice. (H) Kaplan–Meier survival analysis of mice with GSC 157 tumor xenografts (n = 6 per group). **P < 0.01, ***P < 0.001, by two-tailed Student’s t-test, one-way ANOVA, or log-rank analysis.